Home > Boards > US OTC > Biotechs >

Mateon Therapeutics Inc. (MATN)

MATN RSS Feed
Add MATN Price Alert      Hide Sticky   Hide Intro
Moderator: mick
Search This Board: 
Last Post: 11/4/2020 8:50:20 AM - Followers: 9 - Board type: Free - Posts Today: 0



MY THEORY ON $MATN & $GILD. combination with Remdesivir OR single agent cure for COVID-19


A TGF-beta inhibitor is expected to broadly impacted COVID-19 disease and we would encourage developers of
TGF-beta to collaborate and build on these observations such that we can arrive at a cure for COVID-19- either as single agent or combination with Remdesivir.


$MATN$GILD?????, 6;41 A.M. Mateon Therapeutics Appoints Dr. Anthony Maida as Chief Clinical Officer - Translational Medicine
6:41 am ET July 7, 2020 (Globe Newswire) Print
Company expands its management team to accelerate the evaluation of OT-101 for Oncology and COVID-19

[below][ OT-101, a TGF-Beta antisense drug candidate]

Mateon Therapeutics (OTC.QB: MATN), a late-stage biotechnology company developing Trabedersen (OT-101), a TGF-B inhibitor with the
potential for multiple therapeutic indications including glioblastoma, pancreatic cancer,
melanoma and COVID-19, appointed Anthony Maida, III, Ph.D., MA, MBA as Chief Clinical Officer - Translational Medicine for the Company.

Dr. Maida, a director of the Company since 2015, will retain his position as Board of Director. Dr. Maida is an expert in the clinical development of immuno-oncology and related products.

For close to 30 years, Dr. Maida has been involved in all aspects of commercial clinical,
preclinical and scientific development of biotherapeutics including translational medicine,
protocol design, FDA interactions, manufacturing process validation, and data assessment.

He has served in numerous executive and C-suite roles including Chairman, Chief Executive Officer (CEO), Chief Operating Officer (COO),
Chief Scientific Officer (CSO), and Chief Financial Officer (CFO) for companies ranging from startups to public companies.

Dr. Maida has served on
multiple Boards of Directors and
Advisory Boards for public and
private companies,
hedge funds,
venture capital and pharma.

He is a member of the American Society of Clinical Oncology (ASCO),
the American Association for Cancer Research (AACR),
the Society of Neuro-Oncology (SNO),
the International Society for Biological Therapy of Cancer (iSBTC),
and the American Chemical Society (ACS).

Prior to graduate school,
Dr. Maida was Senior Controller for Lockheed Missile and Space Company,

reporting on $1.7 billion in revenue, and Vice President Finance - CFO of Lockheed DataPlan, Inc.

Dr. Maida holds a Ph.D. in Immunology (tumor immunology),
Master Degree in Toxicology,
an MBA and
two bachelor degrees (history and biology).

Dr. Maida, commented, "I look forward to driving the clinical development of OT-101 to its eventual approval as therapeutic
against COVID-19 and other indications.

The Mateon team has done a tremendous job bringing OT-101 to this stage of development and
I look forward to working closely with the entire clinical team,
our patients, our investigators, and our collaborators."

Dr. Vuong Trieu, Chief Executive Officer of Mateon said,
"We are honored that Dr. Maida has accepted the additional responsibilities within the Company.

With Dr. Maida at the helm we have further strengthened our clinical operation to deliver shareholder values across our therapeutic platforms."

About Coronavirus Disease 2019

Mateon is currently developing OT-101 as a TGF-B inhibitor against the TGF-B surge associated with COVID-19 that potentially drive the diverse clinical symptoms observed with COVID-19.

Coronavirus entry into cells is followed by suppression of cellular replication and redirection of cellular machineries to the replication of the virus.
Cell cycle arrest is also centrally mediated by up-regulation of TGF-B. SARS coronavirus upregulates TGF-B via its nucleocapsid protein
and papain-like protease (PLpro). SARS coronavirus PLpro activates TGF-B1 transcription both in cell-based assay and in mouse model
with direct pulmonary injection. TGF-B overexpression in SARS patients lung samples also been demonstrated.
Suppression of TGF-B expression by OT-101 suppressed SARS-CoV1 and SARS-CoV2 replication in the viral replication assays.
This means as viral load increases there will be a proportional increase in TGF-B which in turn drives the progression of COVID-19 disease.
By targeting TGF-B, OT-101 shuts off the engine behind COVID-19 allowing patients to recover without going into respiratory crisis. In fact,
the administration of a soluble type II TGF-B receptor, which sequesters free TGF-B during lung injury and
protected wild-type mice from pulmonary edema induced by bleomycin or Escherichia coli endotoxin.

Furthermore, mice specifically lacking bronchial epithelial TGF-b1 (epTGFbKO) displayed marked protection from influenza-induced weight loss, airway inflammation, and pathology.

Additionally, these mice exhibited a heighted antiviral state resulting in impaired viral replication in epTGFbKO mice.

Their publication succinctly described the impact of TGF-B suppression against viral infection and we would propose that TGF-beta inhibitor
would result in very similar if not the same protective responses against COVID-19.

***** [$MATN & $GILD MARRIAGE ?????][combination with Remdesivir.cure for 
cCOVID-19- either as single agent]*****
A TGF-beta inhibitor is expected to broadly impacted COVID-19 disease and we would encourage developers of TGF-beta to collaborate and
build on these observations such that we can arrive at a cure for c
COVID-19- either as single agent or combination with Remdesivir.

About Mateon's Lead Product Candidate, OT-101

High-grade gliomas (HGG) are characterized by a T-cell exhaustion signature and pronounced T-cell hyporesponsiveness of their tumor microenvironment (TME).
Transforming growth factor beta 2 (TGF- B2) has been implicated as a key contributor to the immunosuppressive landscape of the TME in HGG. OT-101, a first-in-class
RNA therapeutic designed to abrogate the immunosuppressive actions of TGF- B2, is Oncotelic's lead anti-brain tumor drug candidate. OT-101 has been granted orphan
designation by the FDA under the Orphan Drug Act (ODA). ODA provides for granting special status to a drug to treat a rare disease or condition upon request of a drug company.
Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, including tax credits for qualified clinical testing.
In a completed Phase 2 clinical study, OT-101 exhibited clinically meaningful single-agent activity and induced durable complete and
partial responses in recurrent and refractory adult HGG patients, including young adults with GBM or AA.

About Mateon Therapeutics

Mateon was created by the recent reverse merger with Oncotelic which became a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) creating an immuno-oncology company dedicated to the

development of first in class RNA therapeutics as well as small
molecule drugs against cancer.

OT-101, the lead immuno-oncology drug candidate of Mateon/Oncotelic, is a first-in-class anti-TGF beta RNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer patients in clinical trial settings.

Mateon/Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on pediatric cancer patients.

Mateon has rare pediatric designation for DIPG (CA4P) and melanoma (CA4P). For more information, please visit
http://www.oncotelic.com and

http://www.mateon.com.

Mateon's Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects,
plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism",
"design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift",
"high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements.
Forward-looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing,
clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and
the potential use of the company's product candidates to treat various cancer indications. Each of these forward-looking statements involves risks
and uncertainties and actual results may differ materially from these forward-looking statements.
Many factors may cause differences between current expectations and actual results,
including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected,
changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or
product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks,
including the risk factors described in the company's annual report on Form 10-K filed with the SEC on May 20, 2020 and in the company's other periodic filings.
Forward-looking statements are based on expectations and assumptions as of the date of this press release.
Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations,
whether as a result of new information future events, or otherwise.

Contact Information:

For Mateon Therapeutics, Inc.:

Amit Shah

ashah@oncotelic.com

https://ml.globenewswire.com/media/504ea3c8-34a5-4a06-b98b-94c5f831a368/small/mateonlogo-jpg.jpg




 



OTCQB Member Since 06/2018
OTCQB
OTCQB Venture
Verified Profile 11/2019
Transfer Agent Verified
https://www.otcmarkets.com/stock/MATN/quote
MATN SECURITY DETAILS

Share Structure

Market Cap Market Cap
15,764,870
06/23/2020
 
Authorized Shares   150,000,000
06/19/2020
 
Outstanding Shares
87,582,609   06/19/2020
 
Restricted
Not Available
 
Unrestricted
Not Available
 
Held at DTC
45,859,200
06/19/2020
 
Float
26,844,777
05/08/2020
 
Par Value
No Par Value
 
Market Value calculated only for respective security
 

Transfer Agent

Shareholders

Shareholders of Record   62
05/14/2020
 

Investor Overview

http://investor.mateon.com/
Press Releases
Mar 02, 2020
https://www.oncotelic.com/management/
https://www.oncotelic.com/oxi4503/
https://www.oncotelic.com/collaboration-opportunities/
https://www.oncotelic.com/covid-19/
 
#3, Paycheck Protection Program Promissory Note dated April 21, 2020 between Mateon Therapeutics, Inc. and Silicon Valley Bank.
 
Current Report Filing (8-k) Edgar (US Regulatory) - 4/27/2020 2:47:38 PM
 
https://ih.advfn.com/stock-market/USOTC/mateon-therapeutics-qb-MATN/stock-news/82316246/current-report-filing-8-k
 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, DC 20549 
 
FORM 8-K 
 
CURRENT REPORT
 
=========================================================
 
Item 1.01 Entry into a Material Definitive Agreement.
 
On April 21, 2020, Mateon Therapeutics, Inc. (the "Company"), entered into a Paycheck Protection Program Promissory Note (the "PPP Note")
with respect to a loan in the amount of $250,000 (the "PPP Loan") from Silicon Valley Bank (the "Lender").
The PPP Loan was obtained pursuant to the Paycheck Protection Program (the "PPP") of the Coronavirus Aid, Relief,
and Economic Security Act (the "CARES Act") administered by the U.S. Small Business Administration ("SBA").
The PPP Loan matures on April 21, 2022 and bears interest at a rate of 1.00% per annum.
The PPP Loan is payable in 17 equal monthly payments commencing November 21, 2020.
The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties.
 
All or a portion of the PPP Loan may be forgiven by the SBA and the Lender upon application by the Company within 60 days
but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the SBA requirements. 
 
Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, and
covered utilities during the eight week period commencing on the date of loan approval.
 
For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $100,000, prorated annually. 
 
Not more than 25% of the forgiveness amount may be for non-payroll costs. 
 
Forgiveness is reduced if full- time headcount declines, 
or if salaries and wages of employees with salaries of $100,000 
or less annually are reduced by more than 25%. 
 
After approval of the forgiveness amount and 6 month deferral period, the Lender will provide the Company with
written notification of re-amortization of the PPP Loan and the remaining balance.
 
The foregoing description of the PPP Loan is qualified in its entirety by reference to the PPP Note filed as Exhibit 10.1 to this report and incorporated by reference herein.
 
Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant. 
 
The disclosure under Item 1.01 above is incorporated by reference in this Item 2.03. 
 
Item 9.01 Financial Statements and Exhibits. 
 
See Exhibit Index. 
 
Exhibit Index
 
Exhibit No. Description
   
EX-10.1
 
Paycheck Protection Program Promissory Note dated April 21, 2020 between Mateon Therapeutics, Inc. and Silicon Valley Bank.
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Mateon Therapeutics Inc   
Date: April 27, 2020 By: /s/ Vuong Trieu
  Name: Vuong Trieu
  Title: Chief Executive Officer



https://www.oncotelic.com/covid-19/



COVID-19

Medical-Scientific Rationale for a Randomized, Placebo-Controlled, Phase 2 Study of Trabedersen/OT-101 in COVID-19 Patients with Hypoxemic Respiratory Failure by Dr. Fatih Unckun and Vuong Trieu.

Annals of Pulmonary and Critical Care Medicine (APCCM) a peer-reviewed online publishing journal.

The company has been focused on advancing OT-101 as an immunotherapy for the treatment of cancer and the program is ready for advancement into phase 3 studies based on data from over 200 patients that support its activity and safety.

Upon assessing the broad impact of the SARS-CoV-2 virus and associated COVID-19 complications the company tested its lead compound that showed potent activity in the lab and promising data for treating the virus infection and associated complications based on the OT-101 mechanism of action.

Mateon has two candidates, OT-101 (Trabedersen) and Artemisinin, that can immediately be advanced in COVID-19 clinical trials.

FDA has been engaged for OT-101 for a COVID-19 patient study

Collaboration Opportunities

 

Oncotelic is actively seeking collaborations with corporations, academic institutions, and patient groups to advance our programs.
We have a history of successful partnerships and welcome new collaboration and licensing opportunities.

Interested parties may contact:
Chulho Park PhD,  Chief Technology Officer
Oncotelic Inc.
29397 Agoura Rd., Suite 107
Agoura Hills, CA 91301
bd@oncotelic.com
(650) 635-7000

Partners

The Christie Hospital NHS Foundation Trust

Through our history of collaborative research, Mateon has supported clinical research projects in the United Kingdom (UK) led by
Cancer Research UK (CRUK) along with additional academic partners.
Currently, we are supporting the PAZOFOS study (NCT02055690), which is being led by The Christie Hospital NHS Foundation Trust
and coordinated by the Manchester Academic Health Science Centre,

Trials Coordination Unit, or MAHSC-CTU, with additional support from The University of Manchester, the Royal Marsden NHS Foundation Trust,
and Mount Vernon Cancer Centre (part of the East and North Hertfordshire NHS Trust).
This Phase 1b/2 study is evaluating the combination of CA4P (fosbretabulin) with the tyrosine kinase inhibitor pazopanib (Votrient®) versus pazopanib
alone for the treatment of advanced recurrent ovarian cancer.
We are providing CA4P for use in this trial.

University of Kentucky, Markey Cancer Center

Continuing in our history of collaborative research, Mateon is providing investigational drug to the Markey Cancer Center for their study Study MCC-2016-08 (NCT03014297).
The study is designed as a single center, open label, phase 1 clinical trial for patients with grade 1-3 gastroenteropancreatic neuroendocrine tumors.

In the first part of the study, up to 15 patients will be treated with everolimus in combination with two different dosing regimens of
CA4P to establish appropriate CA4P dosing levels and evaluate the safety of the drug combination.  
The second part of the study is designed to enroll 15 additional patients for assessment of additional safety and efficacy data.
Patients enrolled in MCC-2016-088 will be treated with CA4P and everolimus for 12 weeks.
 

We are committed to leveraging our intellectual property and the product development expertise of our highly experienced management team to enable
vascular targeted therapy to realize its true potential and to bring much needed new therapies for orphan oncology indications to cancer patients worldwide.

We have a portfolio of preclinical and clinical stage candidates focused on areas of significant unmet need that we believe can bring significant value to our shareholders.

Our common stock is traded on the OTCQB Market under the symbol “MATN”.

We are headquartered in Agoura Hills, California

https://www.oncotelic.com/pointr-data/
 

EdgePoint

About EdgePoint Inc.

https://www.oncotelic.com/pointr-data/

EdgePoint AI was established in order to advance the company’s revolutionary cluster-computer platform for AI that processes machine learning
models at a fraction of the power and budget of mainstream computing in pharmaceutical manufacturing.
The company’s technology solution “TrustPoint” provides an AI computing platform for pharmaceutical and healthcare verticals
including blockchain support for manufacturing where data integrity and security are of utmost importance.

EdgePoint is composed of a team of executives with pharmaceutical drug development, GMP manufacturing and deep AI knowledge.

The team includes Steven King who was the former CEO of Peregrine Pharmaceuticals, Inc. (NASDAQ) and its wholly-owned
contract biomanufacturing subsidiary Avid Bioservices, Inc., for over 15 years, during which time the company advanced its
lead compound through Phase 3 development, while growing revenues to over $55 million;
Seasoned executive, Saran Saund who has been founder, CEO and GM at several startups and public companies for which he returned
significant value to shareholders in his startups and chief technology officer; Burcak Beser who has been founder and
CTO of several successful private and public companies with over 144 patents during his career; and Lisa Stepp with broad experience in
executive leadership across geographies and in all aspects of drug development and program management.
The core technology platform for EdgePoint AI came from PointR -which was acquired by Mateon in Nov 2019. Examples of PointR capabilities are shown below.



http://oncotelic.com/wp-content/uploads/LosAngelesBusinessJournal2018-05-21.pdf
Health Care: Drug Developer Adds Digital Monitor



TWO YEAR CHART: NASDAQ

 

$MATN Mateon is Selected by IBM Watson Health for the Use of IBM Clinical Development Solution at No Cost for Phase II Clinical Trial of OT-101 for COVID-19
Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s effort to help support and accelerate promising clinical COVID-19 candidates

https://www.globenewswire.com/news-release/2020/06/24/2052621/0/en/Mateon-is-Selected-by-IBM-Watson-Health-for-the-Use-of-IBM-Clinical-Development-Solution-at-No-Cost-for-Phase-II-Clinical-Trial-of-OT-101-for-COVID-19.html

June 24, 2020 07:00 ET | Source: Mateon Therapeutics
AGOURA HILLS, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of innovative treatments for cancer and other indications with unmet medical needs, announced today that IBM has granted access to its IBM Clinical Development (ICD) platform free of charge for the clinical trial evaluating the potential of Mateon’s lead drug candidate OT-101 in COVID-19 patients. The award was made following IBM’s review of the program and is designed to help accelerate the upcoming phase II COVID-19 clinical trial. IBM is supporting COVID-19 clinical research through an initiative to help support trial sponsors with promising therapeutic and vaccine candidates.

“We are working tirelessly to ensure that OT-101 proves to be safe and efficacious for patients with COVID-19. It is clear that we are going to need the most innovative and nimble partners as we apply the latest technologies and endeavor to develop meaningful treatments for COVID-19 patients,” said Vuong Trieu, CEO, Mateon Therapeutics. “We believe that the IBM Clinical Development solution can be extremely valuable in creating the efficiencies needed to accelerate the clinical trial process.”

The ICD platform offering from IBM Watson Health is a cloud-based, end-to-end clinical development system used by leading CROs and designed to reduce the time and cost of clinical trials. ICD solutions include electronic patient reported outcomes (ePRO), data integration, reporting and analytics, quality and compliance, medical coding, endpoint analysis, randomization, and clinical trial supply management. Remote monitoring of patients is possible through the system’s ePRO technology, which could become crucial in rapidly completing clinical studies as new “hot-spots” of infection arise across the globe.

“The COVID-19 pandemic is an unprecedented global public health crisis and there is an increasing sense of urgency to develop safe and effective treatments as infection rates continue to escalate at an alarming rate,” said Mary Varghese Presti, Vice President, Life Sciences, IBM Watson Health. “We are committed to leveraging our ICD solution to help accelerate the timelines for COVID-19 clinical trials and are enabling access to the platform, free of charge, for relevant trial sponsors. We are inspired by Mateon’s commitment, as well as all of the other leaders in the life sciences community, as they apply their expertise and ingenuity to help millions of patients worldwide. IBM is proud to play a meaningful role in this ambitious effort.”

About Mateon Therapeutics
Mateon was created by the recent reverse merger with Oncotelic which became a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) creating an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer. OT-101, the lead immuno-oncology drug candidate of Mateon/Oncotelic, is a first-in-class anti-TGF beta RNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer patients in clinical trial settings. The founding team members of Oncotelic were responsible for the development of Celgene’s Abraxane as a chemotherapeutic agent for breast, lung, melanoma, and pancreatic cancer. Abraxane was approved in 2005 and has more than $1B in sales annually. The same team was also responsible for the development of Cynviloq, a next generation Abraxane, which was acquired by NantPharma for $1.3B. Mateon/Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on pediatric cancer patients. For more information, please visit www.oncotelic.com and www.mateon.com.

About Mateon’s Lead Product Candidate, OT-101
High-grade gliomas (HGG) are characterized by a T-cell exhaustion signature and pronounced T-cell hyporesponsiveness of their tumor microenvironment (TME). Transforming growth factor beta 2 (TGFB2) has been implicated as a key contributor to the immunosuppressive landscape of the TME in HGG. OT101, a first-in-class RNA therapeutic designed to abrogate the immunosuppressive actions of TGFB2, is Oncotelic’s lead anti-brain tumor drug candidate. OT101 has been granted orphan designation by the FDA under the Orphan Drug Act (ODA). ODA provides for granting special status to a drug to treat a rare disease or condition upon request of a drug company. Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, including tax credits for qualified clinical testing. In a completed Phase 2 clinical study, OT-101 exhibited clinically meaningful single-agent activity and induced durable complete and partial responses in recurrent and refractory adult HGG patients, including young adults with GBM or AA.

Mateon's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as “may”, “expect”, “anticipate” “hope”, “vision”, “optimism”, “design”, “exciting”, “promising”, “will”, “conviction”, "estimate," "intend," "believe", “quest for a cure of cancer”, “innovation-driven”, “paradigm-shift”, “high scientific merit”, “impact potential” and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company’s product candidates and the potential use of the company’s product candidates to treat various cancer indications. Each of these forward-looking statements involves risks and uncertainties and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the company’s annual report on Form 10-K filed with the SEC on April 10, 2019 and in the company’s other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information future events, or otherwise.

Contact Information:
For Mateon Therapeutics, Inc.:
Amit Shah
ashah@oncotelic.com


Related Articles
More articles issued by Mateon Therapeutics
More articles related to:
Health




 
*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.


 



 

MATN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#248  Sticky Note $MATN & $GILD?????,6;41a.m. 07-07-2020 .M. Mateon Therapeutics Appts. mick 07/28/20 06:25:22 PM
#297   MATEON’S C001- A GLOBAL PHASE 2 STUDY FOR subslover 11/04/20 08:50:20 AM
#296   Mateon/MATN was formerly OxiGENE/OXGN, before the reverse split. gi197845 11/02/20 09:10:40 PM
#295   ArtiShield PinkOnion 11/02/20 08:21:59 AM
#294   ArtiShield PinkOnion 11/02/20 08:21:51 AM
#293   https://www.globenewswire.com/news-release/2020/11/02/2118317/0/en/MATEON-TO-HOS PinkOnion 11/02/20 08:20:56 AM
#292   Mateon Therapeutics (MATN) mick 10/25/20 04:52:04 PM
#291   What makes you think I'm not in MATN? gi197845 10/07/20 11:52:46 AM
#290   Not different than the rest of the otc StockingStuffer1000 10/07/20 10:11:02 AM
#289   MATN, formerly OXGN has had a long history gi197845 10/07/20 10:04:52 AM
#288   not good. didn't see it had financing StockingStuffer1000 10/07/20 09:11:43 AM
#287   How's that run to .35? gi197845 10/06/20 11:59:40 PM
#286   Mateon Therapeutics (MATN) mick 09/24/20 08:49:30 PM
#285   Mateon Therapeutics (MATN) mick 09/05/20 03:10:10 PM
#284   $MATN MATEON THERAPEUTICS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS mick 08/24/20 02:26:32 PM
#283   $MATN MATEON THERAPEUTICS AND ABIOGENESIS TO INITIATE CLINICAL mick 08/24/20 02:05:58 PM
#282   $MATN MY FAVORITE mick 08/24/20 01:58:40 PM
#281   What is going on with the US FDA Birddogfishman 08/20/20 04:53:00 PM
#280   Not hearing anything...they had this a bit ago.. Golden_Cross 08/20/20 12:15:06 PM
#279   $MATN ANY NEWS ????? mick 08/20/20 11:32:38 AM
#278   MATEON THERAPEUTICS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS mick 08/18/20 01:22:29 PM
#277   Mateon Therapeutics (MATN) mick 08/15/20 11:54:00 PM
#276   $MATN Mateon Therapeutics (MATN) mick 08/05/20 10:31:51 AM
#275   $MATN ON TARGET mick 08/05/20 10:31:36 AM
#274   Sure, noticed that cross the other day on Golden_Cross 08/04/20 03:15:55 PM
#273   $MATN thank for charting mick 08/04/20 02:25:53 PM
#272   $MATN MATEON THERAPEUTICS AND ABIOGENESIS TO INITIATE CLINICAL mick 08/04/20 02:22:14 PM
#271   Chart had a cross of the 50/200sma today...$MATN Golden_Cross 07/30/20 08:42:36 PM
#270   all in for meee,$$$$$$ MHOP kingsransome 07/29/20 09:44:00 AM
#269   .29 pre-market print on only 250 shares traded. StockingStuffer1000 07/29/20 08:52:33 AM
#268   $MATN;AGOURA HILLS, Calif., July 27, 2020 (GLOBE NEWSWIRE) mick 07/28/20 07:19:41 PM
#267   $MATN #2 $MATN MATEON AND ASILI RESEARCH ALLIANCE mick 07/28/20 07:04:12 PM
#266   $MATN MATEON AND ASILI RESEARCH ALLIANCE ENTER INTO mick 07/28/20 07:01:08 PM
#265   $MATN - Stonegate Capital Partners Initiates Coverage on mick 07/28/20 06:58:51 PM
#264   $MATN https://otcbb.swingtradebot.com/equities/MATN mick 07/28/20 06:56:26 PM
#263   $MATN mick 07/28/20 06:55:52 PM
#262   $MATN Mateon Report Positive Results for Multiple COVID-19 mick 07/28/20 06:54:59 PM
#261   $MATN, COULD BE HUGE WINNER. THEY HAVE HERB mick 07/28/20 06:52:22 PM
#260   $MATN, name of herb, ARTEMISIA --- ALSO WORMWOOD [extract] mick 07/28/20 06:51:49 PM
#259   $MATN https://www.barchart.com/stocks/quotes/MATN/cheat-sheet mick 07/28/20 06:49:33 PM
#258   $MATN Barchart Technical Opinion STRONG BUY[72% Buy with mick 07/28/20 06:48:38 PM
#257   $MATN http://www.barchart.com/quotes/stocks/MATN mick 07/28/20 06:46:52 PM
#256   $MATN [-chart]www.stockta.com/cgi-bin/candle.pl?cobrand=&symb=MATN&size=analysis mick 07/28/20 06:46:09 PM
#255   $MATN https://www.oncotelic.com/pipeline/ mick 07/28/20 06:43:25 PM
#254   $MATN I LIKE UPTICKS !!!!! MAYBE $GILD BUYOUT ????? mick 07/28/20 06:42:12 PM
#253   $MATN MY THEORY ON $MATN & $GILD. combination mick 07/28/20 06:41:05 PM
#252   $MATN https://www.oncotelic.com/pointr-data/ mick 07/28/20 06:39:39 PM
#251   $MATN https://www.oncotelic.com/pipeline/ mick 07/28/20 06:39:11 PM
#250   $MATN EXCERPT; OT-101 is also being deployed as mick 07/28/20 06:37:56 PM
#249   $MATN Press Release huge reading !!!!! May 05, 2020 mick 07/28/20 06:36:59 PM
#248   $MATN & $GILD?????,6;41a.m. 07-07-2020 .M. Mateon Therapeutics Appts. mick 07/28/20 06:25:22 PM
PostSubject
Consent Preferences